Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies.

ABSTRACT:

Introduction

A novel, red-shifted bioluminescence imaging (BLI) system called AkaBLI has been recently developed for cell tracking in preclinical models and to date, limited data is available on how it performs in relation to existing systems.

Purpose

To systematically compare the performance of AkaBLI and the standard Firefly luciferase (FLuc) systems to monitor the biodistribution and fate of cell therapies in rodents.

Methods

Umbilical cord mesenchymal stromal cells (MSCs) were transduced to produce two genetically engineered populations, expressing either AkaLuc or the engineered FLuc luc2. The bioluminescence of AkaLuc⁺ and FLuc⁺ cells was assessed both in vitro (emission spectra, saturation kinetics and light emission per cell) and in vivo

SUBMITTER: Amadeo F 

PROVIDER: S-EPMC8803776 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature